(2)(2)(2) NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance while revising its November 4, 2025 full-year 2025 Revenue guidance and reaffirming all other components of full- year 2025 financial guidance. The accompanying presentation can be found at www.pfizer.com/investors. (2)FULL-YEAR 2026 REVENUE GUIDANCE (2)(2)(2)(3) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance is revised to appr ...

Core Viewpoint - Enbridge Inc. announced its 2026 financial guidance, projecting steady growth driven by new projects and strong utilization of existing assets, alongside a 3% increase in its annual common share dividend [1][2]. Financial Guidance - The company provided 2026 adjusted EBITDA guidance of CAD 20.2 billion to CAD 20.8 billion and distributable cash flow (DCF) per share guidance of CAD 5.70 to CAD 6.10 [1]. - Enbridge reaffirmed its 2025 full-year guidance, expecting to finish in the upper half of the EBITDA range of CAD 19.4 billion to CAD 20.0 billion and at the midpoint for DCF per share [1]. - The company anticipates a compound annual growth rate of 7-9% for EBITDA, 4-6% for adjusted earnings per share (EPS), and approximately 3% for DCF per share from 2023 to 2026 [1]. Dividend Increase - Enbridge declared a 3% increase in its quarterly common share dividend from CAD 0.9425 to CAD 0.97, effective March 1, 2026, marking the 31st consecutive annual increase [1]. Growth Drivers - The projected EBITDA for 2026 is supported by approximately CAD 8 billion of new projects entering service, strong growth from recent rate settlements, and optimization of existing assets [1]. - Key growth drivers include contributions from organic projects, increased rates on U.S. Gas Transmission assets, and favorable re-contracting [1]. Capital Investments and Financing - Enbridge plans to deploy approximately CAD 10 billion of growth capital in 2026, with a strong balance sheet and a debt-to-EBITDA ratio expected to remain within the target range of 4.5-5.0x [1]. - The financing plan includes CAD 10 billion of debt issuances, primarily for refinancing CAD 5 billion of debt maturities, with no external equity required [1].

Financial advisor and financial planner roles are both very broad categories. Know the differences when you're looking for professional financial guidance. https://t.co/dOiIoAFm0V ...

Core Insights - Shake Shack's CFO, Katherine Fogertey, will leave the company on March 4, 2026, transitioning to a senior advisor role immediately to assist in the handover process [1] - The company is initiating a search for a new CFO and has established an Office of the CFO to ensure stability during the transition [2][3] - Shake Shack has reiterated its financial guidance for Q4 2025 and the full year, projecting total revenue growth of 16% year-on-year for 2025 [4][5][6] Financial Guidance - For Q4 2025, Shake Shack forecasts total revenue between $406 million and $412 million, with licensing revenue expected to be between $15.4 million and $15.7 million [5] - Same-Shack sales are anticipated to increase by a low single-digit percentage compared to the same period last year [5] - For the full year 2025, total revenue is projected at approximately $1.45 billion, with licensing revenue expected between $54.1 million and $54.5 million [5][6] Strategic Goals - The company maintains its guidance for adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in the range of $210 million to $215 million for fiscal year 2025 [6] - Shake Shack's three-year targets remain unchanged, aiming for total revenue growth and system-wide unit expansion in the low-teens percentage range [6]

Core Viewpoint - StubHub's stock experienced a significant decline of 24% following the company's decision to withhold financial guidance for the current quarter, emphasizing a long-term focus instead [1][2]. Financial Performance - StubHub reported stronger-than-expected third-quarter results, with revenue increasing by 8% year over year to $468.1 million, surpassing the average analyst estimate of $452 million [3]. - Gross merchandise sales rose by 11% year over year to $2.43 billion, exceeding Wall Street's expectation of $2.36 billion [3]. Management Commentary - CEO Eric Baker highlighted that the timing of ticket sales can vary from quarter to quarter, complicating predictions of consumer demand [1]. - Baker stated that demand for live events remains "phenomenal" and indicated that the company plans to provide an outlook for 2026 during the fourth-quarter results announcement [2]. Analyst Reaction - Wedbush analysts expressed surprise at the lack of forward guidance from StubHub executives, noting that this decision could pressure shares and raise investor concerns about near-term visibility [2].

Core Insights - Acadia Healthcare Company, Inc. (ACHC) reported adjusted third-quarter earnings of 72 cents per share, exceeding the Zacks Consensus Estimate by 7.5%, but reflecting a year-over-year decline of 20.9% [1][9] - Total revenues increased by 4.4% year over year to $851.6 million, slightly surpassing the consensus mark by 0.4% [1][9] Financial Performance - Same-facility revenues reached $827.8 million, a 3.7% increase year over year, but fell short of the Zacks Consensus Estimate by 1.4% [3] - Patient days increased by 1.3%, while admissions grew by 3.3% year over year [3] - Average length of stay decreased by 1.9% year over year, missing the consensus estimate by 3.2% [3] - Total expenses rose by 13.2% year over year to $811.6 million, driven by higher salaries, wages, benefits, and other operating costs [4] Cash and Debt Position - As of September 30, 2025, Acadia Healthcare had cash and cash equivalents of $118.7 million, up from $76.3 million at the end of 2024 [5] - Long-term debt increased to $2.3 billion from $1.9 billion as of December 31, 2024 [6] - Total equity rose to $3.1 billion compared to the end of 2024 [6] Share Repurchase and Guidance - Year-to-date share repurchases totaled $50.4 million, with no buyback activity in the third quarter [7] - 2025 revenue guidance was revised down to a range of $3.28 to $3.30 billion, and adjusted EBITDA is now estimated between $650 million and $660 million [8][10] Industry Comparison - HCA Healthcare reported adjusted EPS of $6.96, surpassing estimates by 23.2% and showing a 42% year-over-year improvement [12] - Universal Health Services reported adjusted EPS of $5.69, exceeding estimates by 22.1% and reflecting a 53.4% year-over-year increase [13] - Community Health Systems posted adjusted earnings of $1.27 per share, beating estimates and improving from a prior-year loss [14]

Core Insights - Interparfums, Inc. reported third-quarter 2025 results with earnings of $2.05 per share, a 6% increase from $1.93 in the prior year, surpassing the Zacks Consensus Estimate of $1.85 per share [3][9] - Consolidated net sales reached $429.6 million, reflecting a 1% increase from $424.6 million in the same period last year, driven by strong consumer interest in prestige and luxury fragrances [3][9] Financial Performance - The consolidated gross margin was 63.5%, down 40 basis points from the previous year, primarily due to increased U.S. import tariffs [4] - Selling, general and administrative expenses accounted for 38.2% of net sales, a decrease of 70 basis points year over year, with advertising and promotional expenditures at 15.3% of net sales [5] - Operating income was $108.6 million, with an operating margin of 25.3%, up from 25% in the prior year [5] Financial Health - The company ended the quarter with cash and cash equivalents of $110.4 million, long-term debt of $140 million, and total equity of $1,104.5 million [6] - A cash dividend of 80 cents per share was announced, payable on December 31, 2025, to shareholders of record as of December 15 [6] Future Outlook - Interparfums revised its 2025 sales outlook to $1.47 billion, a 1% year-over-year increase, down from the previous guidance of $1.51 billion [7][8] - The earnings per share forecast for 2025 is now $5.12, consistent with 2024 levels, compared to the earlier expectation of $5.35 [8]

Core Insights - North Media's Q3 2025 performance showed a slight decline in activity levels, with revenue decreases in both Last Mile and Digital Services, but operating profit growth in Digital Services due to reduced losses in Dayli and Bekey [1][2] Financial Performance - Q3 2025 revenue was DKK 286.4 million, down from DKK 299.4 million in Q3 2024, while year-to-date revenue decreased by 2% to DKK 939.2 million [2][6] - EBITDA for Q3 2025 was DKK 12.1 million compared to DKK 19.4 million in the previous year, with year-to-date EBITDA at DKK 71.1 million, down from DKK 120.9 million [2][6] - EBIT for Q3 2025 was -DKK 1.7 million, a decline from DKK 3.0 million in Q3 2024, with a year-to-date EBIT of DKK 29.3 million compared to DKK 59.2 million [2][7] - The EBIT margin for Q3 2025 was -0.6%, down from 1.0% in the previous year, while the year-to-date EBIT margin was 3.1%, down from 6.2% [2][7] Business Area Performance - Last Mile reported Q3 2025 revenue of DKK 247 million, a 4% decrease from Q3 2024, with some positive effects from repatriating invoicing from former franchisees [3] - Digital Services saw a 4% revenue decline to DKK 40 million, primarily due to lower advertising revenue in BoligPortal and a slight setback in Dayli, but EBITDA improved to a profit of DKK 3 million from a loss of DKK 3 million in the previous year [5][6] Operational Developments - The integration of SDR into North Media reached a significant milestone with the completion of automated packing for the Swedish market, expected to lead to long-term cost reductions [1] - The transition costs associated with the automated packing in Sweden impacted EBITDA, but Digital Services reported growth driven by performance improvements in Bekey [6] Guidance for 2025 - The company narrowed its full-year financial guidance for 2025, with expected revenue between DKK 1,270 million and DKK 1,305 million, EBITDA between DKK 105 million and DKK 126 million, and EBIT between DKK 50 million and DKK 70 million [8][13]

Core Viewpoint - Snowflake Inc faced scrutiny after an executive provided unauthorized financial guidance in a public interview, prompting the company to file a report with the Securities and Exchange Commission to clarify that the statements should not be relied upon by investors [1][2][3] Group 1: Unauthorized Financial Guidance - An unnamed executive from Snowflake shared financial projections during an Instagram interview, stating the company expects to exceed $4.5 billion in revenue for the current year and aims to reach $10 billion in a couple of years [3] - The company emphasized that the executive is not an authorized spokesperson for disclosing financial information, as per its Corporate Disclosure Policy [2] Group 2: Public Response and Impact - The Instagram video featuring the executive has garnered significant attention, with 2.5 million views, indicating a high level of public interest in Snowflake's financial outlook [3] - Snowflake has not provided immediate comments regarding the situation following the unauthorized disclosure [3]

Core Viewpoint - CVS Health Corp reported better-than-expected third-quarter earnings and raised its annual guidance, indicating strong performance across all segments [1][2]. Financial Performance - The company reported sales of $102.87 billion, surpassing the consensus estimate of $98.84 billion, with total revenues increasing by 7.8% year-over-year [2]. - Adjusted earnings per share were $1.60, exceeding the analyst estimate of $1.37, while the GAAP diluted loss per share was $3.13, impacted by a $5.7 billion goodwill impairment charge [2]. - Adjusted operating income rose by 35.8% to $3.46 billion, primarily due to growth in the Health Care Benefits segment [3]. Segment Performance - Revenues in the Health Care Benefits segment increased by 9.1% to $35.99 billion, driven by growth in the Government business, influenced by the Inflation Reduction Act [4]. - The Health Services segment saw sales increase by 11.6% to $49.27 billion, mainly due to pharmacy drug mix and brand inflation [6]. - The Pharmacy & Consumer Wellness segment's sales rose by 11.7% to $36.21 billion, supported by increased prescription volume and acquisitions from Rite Aid [7]. Membership and Metrics - The Medical benefit ratio improved to 92.8% from 95.2%, reflecting favorable developments in health care costs and performance in the Government business [5]. - Medical membership stood at 26.7 million, indicating a stable customer base [5]. - Prescriptions filled increased by 6.9% to 461.4 million, driven by higher utilization and Rite Aid acquisitions [7]. Guidance Update - CVS Health raised its fiscal 2025 adjusted earnings guidance to a range of $6.55-$6.65, compared to the previous range of $6.30-$6.40 [8]. - The company updated its cash flow from operations guidance to $7.5 billion to $8.0 billion, maintaining a minimum of $7.5 billion [8]. - GAAP diluted earnings (loss) per share guidance was revised to a range of $(0.34) to $(0.24), down from $3.84 to $3.94 [8]. Stock Performance - CVS Health shares increased by 2.14% to $83.96, reaching a new 52-week high [10].